Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
RESEARCH TOOLSreports
Holding MDGL?
Track your performance easily
See the Price Targets and Ratings of:
MDGL Analyst Ratings
Moderate Buy
8 Buy
2 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MDGL Stock 12 Month Forecast
Average Price Target
$343.70
▲(47.41% Upside)
| Highest Price Target$415.00 | Average Price Target$343.70 | Lowest Price Target$150.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
Assigned
08/08/24
H.C. Wainwright
Reiterated
08/08/24
Evercore ISI
Assigned
08/08/24
Citi
Reiterated
08/08/24
Leerink Partners
Assigned
08/07/24
TD Cowen
Reiterated
08/07/24
JMP Securities
Reiterated
08/07/24
Canaccord Genuity
Reiterated
08/07/24
Wolfe Research
Reiterated
08/07/24
B.Riley Financial
Reiterated
08/07/24
Cantor Fitzgerald
―
Hold
―
Initiated
06/28/24
Madrigal Pharmaceuticals initiated with a Neutral at Cantor FitzgeraldMadrigal Pharmaceuticals initiated with a Neutral at Cantor Fitzgerald
Oppenheimer
$375
Buy
60.83%
Upside
Reiterated
06/10/24
Oppenheimer Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Piper Sandler
$336
Buy
44.11%
Upside
Reiterated
05/29/24
Analysts Are Bullish on Top Healthcare Stocks: Globus Medical (GMED), Irhythm Technologies (IRTC)
Goldman Sachs
$565→$507
Buy
117.45%
Upside
Reiterated
05/08/24
Madrigal Pharmaceuticals (MDGL) PT Lowered to $507 at Goldman SachsGoldman Sachs analyst Andrea Tan lowered the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $507.00 (from $565.00) while maintaining a Buy rating.
UBS
$337→$410
Buy
75.84%
Upside
Reiterated
03/15/24
Madrigal Pharmaceuticals price target raised to $410 from $337 at UBSMadrigal Pharmaceuticals price target raised to $410 from $337 at UBS
Best Analysts Covering Madrigal Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy MDGL and Sell After:
1 Month
xxx
Success Rate
12/21 ratings generated profit
Average Return
+5.53%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +5.53% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+4.48%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +4.48% per trade.
1 Year
Success Rate
18/32 ratings generated profit
Average Return
+52.22%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +52.22% per trade.
2 Years
xxx
Success Rate
11/14 ratings generated profit
Average Return
+103.55%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +103.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MDGL Analyst Recommendation Trends
Rating
Apr 24
May 24
Jun 24
Jul 24
Aug 24
Strong Buy
17
20
16
15
11
Buy
17
11
2
3
4
Hold
1
2
3
4
4
Sell
3
3
2
1
1
Strong Sell
0
0
0
0
0
total
38
36
23
23
20
Each month's total comprises the sum of three months' worth of ratings.
MDGL Financial Forecast
MDGL Stock Forecast FAQ
What is MDGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is $343.70.
What is MDGL’s upside potential, based on the analysts’ average price target?
Madrigal Pharmaceuticals Inc has 47.41% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MDGL a Buy, Sell or Hold?
Madrigal Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.
What is Madrigal Pharmaceuticals Inc’s price target?
The average price target for Madrigal Pharmaceuticals Inc is $343.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $415.00 ,the lowest forecast is $150.00. The average price target represents 47.41% Increase from the current price of $233.16.
The highest analyst price target is $415.00 ,the lowest forecast is $150.00. The average price target represents 47.41% Increase from the current price of $233.16.
What do analysts say about Madrigal Pharmaceuticals Inc?
Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of MDGL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.